T. Rowe Price Investment Management
IMVT icon

T. Rowe Price Investment Management’s Immunovant IMVT Stock Holding History

T. Rowe Price Investment Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.7M Sell
3,612,860
-1,447,539
-29% -$37.5M 0.06% 269
2025
Q4 		$129M Sell
5,060,399
-104,299
-2% -$2.33M 0.08% 218
2025
Q3 		$83.3M Sell
5,164,698
-1,714,258
-25% -$27.8M 0.05% 298
2025
Q2 		$110M Buy
6,878,956
+984,132
+17% +$14.9M 0.07% 262
2025
Q1 		$101M Buy
5,894,824
+777,590
+15% +$16.3M 0.07% 280
2024
Q4 		$127M Buy
5,117,234
+1,786,217
+54% +$50.7M 0.08% 247
2024
Q3 		$95M Buy
3,331,017
+1,705,797
+105% +$50.3M 0.06% 305
2024
Q2 		$42.9M Buy
+1,625,220
New +$46.2M 0.03% 406

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

T. Rowe Price Investment Management's IMVT Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Immunovant (IMVT) stake by 29% in Q1 2026, selling an estimated $37.5M and leaving 3,612,860 shares worth $89.7M. The position accounts for 0.06% of the portfolio, ranked #269.

T. Rowe Price Investment Management first reported a position in IMVT in Q2 2024 and has held it in 8 quarters since. The position peaked at $129M in Q4 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • T. Rowe Price Investment Management held 3,612,860 shares of Immunovant worth $89.7M as of Q1 2026.
  • T. Rowe Price Investment Management sold 1,447,539 Immunovant shares in Q1 2026, an estimated $37.5M.
  • Immunovant made up 0.06% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #269 holding.
  • T. Rowe Price Investment Management first reported a position in Immunovant in Q2 2024 and has held it in 8 quarters since.
  • T. Rowe Price Investment Management's Immunovant position peaked at $129M in Q4 2025.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.